z-logo
open-access-imgOpen Access
Small Molecule Inhibitors of West Nile Virus
Author(s) -
Samia A. Elseginy,
Alberto Massarotti,
Galal A. M. Nawwar,
Kamilia M. Amin,
Andrea Brancale
Publication year - 2013
Publication title -
antiviral chemistry and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.919
H-Index - 51
eISSN - 2040-2066
pISSN - 0956-3202
DOI - 10.3851/imp2581
Subject(s) - flavivirus , west nile virus , virology , human pathogen , encephalitis , biology , virus , human disease , meningitis , flaviviridae , pathogen , disease , viral disease , medicine , immunology , pediatrics , pathology , genetics , bacteria
West Nile virus (WNV) is a human pathogen which is rapidly expanding worldwide. It is a member of the Flavivirus genus and it is transmitted by mosquitos between its avian hosts and occasionally in mammalian hosts. In humans the infection is often asymptomatic, however, the most severe cases result in encephalitis or meningitis. Approximately 10% of cases of neuroinvasive disease are fatal. To date there is no effective human vaccine or effective antiviral therapy available to treat WNV infections. For this reason, research in this field is rapidly growing. In this article we will review the latest efforts in the design and development of novel WNV inhibitors from a medicinal chemistry point of view, highlighting challenges and opportunities for the researchers working in this field.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom